A Global Approach to Tackle Cognitive Decline
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Enrollment
- 1,502
- Locations
- 1
- Primary Endpoint
- Record of any vascular risk factors
Study Overview
Brief Summary
The number of people suffering from dementia in Asia (22.9 million) is more than twice the numbers in Europe (10.5 million) or the Americas (9.4 million), as recorded in the global impact of dementia in the World Alzheimer Report 2015.1 This dementia tsunami will continue to rise and the estimated number is 67 million in 2050 in Asia alone, which will be 2 to 3 times higher than the estimates for Europe (19 million) or the Americas (30 million). Devising and implementing preventive strategies against dementia is of paramount importance. The proposed project will be able to establish the associations between VRFs and cognition across cohorts with cultural, ethnical, and demographical variations. This study will generate data for evidence-based knowledge for globally implementable and effective preventive strategies for cognitive impairment and dementia.
Detailed Description
Participants will be retrospectively selected from a Hong Kong Chinese cohort, a Singaporean cohort, a British cohort, two European cohorts, and an Australian cohort.
Subjects from the above listed cohorts who fit the study criteria will be selected for this study.
Demographical information, clinical, vascular risk factors, MRI images and cognitive data will be retrieved from the cohorts.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 60 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Elderly community-dwelling individuals aged over 60 years old;
- •those with at least 2 time points of detailed cognitive measurements, with 2-3 years of assessment interval;
- •with at least 1 timepoint of MRI (T1, FLAIR, and DTI).
Exclusion Criteria
- •subjects with stroke, dementia, and other neurological diseases at baseline;
- •those without longitudinal cognitive data;
- •those without MRI data available.
Outcomes
Primary Outcomes
Record of any vascular risk factors
Time Frame: Baseline
medical history of hypertension, diabetes mellitus, hyperlipidemia, smoking and drinking, record unit as yes or no
Record of low-density-lipoprotein level,
Time Frame: Baseline
low-density-lipoprotein level, as one of the vascular risk factors, unit as mmol/L
Record of total cholesterol level,
Time Frame: Baseline
total cholesterol level, as one of the vascular risk factors, unit as mmol/L
Record of pulse
Time Frame: Baseline
Pulse rate, as one of vascular risk factors, unit as bpm
Record of triglyceride level
Time Frame: Baseline
triglyceride level, as one of vascular risk factors, unit as mmol/L
Record of high-density-lipoprotein level,
Time Frame: Baseline
high-density-lipoprotein level, as one of the vascular risk factors, unit as mmol/L
Record of fasting blood glucose
Time Frame: Baseline
fasting blood glucose from blood results, as one of vascular risk factors, unit as mmol/L
Record of glycated hemoglobin
Time Frame: Baseline
glycated hemoglobin, as one of the vascular risk factors, unit as percentage
Change of Montreal Cognitive Assessment
Time Frame: Baseline, 1 yr, 2yr and 3rd year follow ups
Montreal Cognitive Assessment is used for measuring general cognition including the domains of attention and processing speed, executive function, memory, visuospatial function, and animal fluency.
Changes of brain white matter abnormalities
Time Frame: Baseline and 1 yr, 2yr and 3rd year follow ups
brain white matter abnormalities can be observed through the FLAIR sequence of brain MRI images
Record of blood pressure
Time Frame: Baseline
Blood pressure, as one of vascular risk factors, unit as mmHg
Change of Mini-Mental State Examination
Time Frame: Baseline and 3rd year follow up
Mini-Mental State Examination is used for measuring general cognition including the domains of attention and processing speed, executive function, memory, visuospatial function, and animal fluency.
Secondary Outcomes
No secondary outcomes reported
Investigators
Bonnie Yin Ka LAM
Research Assistant Professor
Chinese University of Hong Kong